Pharming (PHAR) Income from Non-Controlling Interests (2025)
Pharming's (PHAR) quarterly Income from Non-Controlling Interests came in at -$313000.0 in Q4 2025, down 285.21% on a QoQ basis from $169000.0 in Q3 2025.
Powered by 
Analysis
Pharming (PHAR) Income from Non-Controlling Interests (2025) Analysis & Trends
Pharming (PHAR) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$313000.0 in Q4 2025.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$313000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$626000.0 (changed N/A YoY) and the FY2025 annual result came in at -$313000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests slipped to -$313000.0 in Q4 2025, from $169000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $169000.0 in Q3 2025 to a low of -$313000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Pharming | 781.07 Mn | 621.57 Mn | 141.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -313,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Mar 31, 2025 | -169,000.00 |